Your session is about to expire
← Back to Search
Talazoparib + Avelumab for Lung Cancer
Study Summary
This trial is testing a combination of two drugs to treat patients with STK11-mutated non-squamous non-small cell lung cancer that has recurred or is stage IV.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 1 & 2 trial • 40 Patients • NCT02116777Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer treatment is based on specific genetic test results.I have had only one or no treatments with anti-PD-1 or anti-PD-L1 for my advanced cancer.I had anti-PD-1 or anti-PD-L1 therapy for stage III disease and my condition worsened within a year.I haven't had any live vaccines in the last 28 days.Your hemoglobin level is at least 9 grams per deciliter.I have never had a bad reaction to immunotherapy that required stopping it or taking high doses of steroids.Your blood platelet count is at least 100,000 per microliter.I haven't taken steroids or immunosuppressants in the last week.My stomach and intestines work well and I don’t have diseases that affect how my body absorbs medicine.I have chronic hepatitis B but it's under control with treatment.My kidney function, measured by creatinine levels, is normal or near normal.I am not using, nor will I use strong medication inhibitors or inducers while on this treatment.I had hepatitis C but am now cured or have no detectable virus.I have HIV, am on treatment, and my viral load is undetectable.I am not planning to receive any other cancer treatments while on this study.I've had a brain scan within the last 42 days to check for brain disease.My lung cancer is advanced or has come back and is not mainly squamous cell type.I haven't taken steroids or immunosuppressants for autoimmune disease in the last week.I do not have any infections that need treatment with medication.I had a physical exam within the last 28 days.I haven't had any cancer treatment in the last 3 weeks.I have not had radiation therapy in the last 14 days.You need to have a visible disease that can be seen on a CT scan or MRI.I have not had any major surgery in the last 14 days.I have not had any other cancer types, except for certain allowed cases.I am fully active or restricted in physically strenuous activity but can do light work.I have been treated with anti-PD-1 or anti-PD-L1 therapy for advanced or recurrent disease.I have never been treated with a PARP inhibitor.I do not have severe heart disease.My cancer returned within a year after completing platinum-based chemotherapy following surgery.My condition worsened after my last treatment.Your bilirubin level in the blood is within the normal range set by the hospital.Your white blood cell count is at least 1,500 per microliter.Your liver enzymes (ALT or AST) are not more than two times the upper limit of normal.My cancer progressed more than 42 days after starting platinum-based chemotherapy without anti-PD-1 or PD-L1 therapy.
- Group 1: Treatment (talazoparib, avelumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Did the FDA green light Talazoparib?
"Talazoparib's safety is only supported by preliminary data, so it received a score of 2."
How many active research sites are there in the United States for this trial?
"100 patients are currently enrolling in this study at Greater Regional Medical Center in Creston, AnMed Health Cancer Center in Anderson, McFarland Clinic PC-Boone in Boone, and other locations."
What does Talazoparib help patients with the most?
"Talazoparib can be used to treat both advanced directives and other conditions like the brca1 gene, merkel cell carcinoma, and malignant neoplasms."
What does the research say about Talazoparib's efficacy?
"City of Hope first began studying talazoparib in 2010 and, since then, 69 clinical trials have completed. As of now, 168 research studies are ongoing; a large proportion of these taking place in Creston, Iowa."
How many individuals are participating in this experiment?
"This study is no longer looking for participants. The trial was originally posted on February 14th, 2020 and updated for the last time on May 3rd, 2022. However, there are currently 5110 other studies that are still enrolling patients with stage iva lung cancer ajcc v8 and 168 studies that involve Talazoparib if you're interested in participating in clinical trials."
How can interested individuals sign up for this research project?
"This particular trial is not currently looking for more patients, as it has already reached its recruitment goal. The study was first posted on February 14th, 2020 and was last updated on May 3rd, 2022. For those still exploring their options, there are 5110 other clinical trials actively recruiting patients with stage iva lung cancer ajcc v8 and 168 trials for Talazoparib admitting patients right now."
Share this study with friends
Copy Link
Messenger